Nisa Investment Advisors
QNCX icon

Nisa Investment Advisors’s Quince Therapeutics QNCX Stock Holding History

Nisa Investment Advisors’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-16
Closed -$20K – 2485
2022
Q1 		$20K Buy
16
+14
+700% +$19.1K ﹤0.01% 2052
2021
Q4 		$2K Hold
2
– – ﹤0.01% 2128
2021
Q3 		$27 Buy
+2
New +$31.8K ﹤0.01% 2038
2021
Q1 		– Sell
-1
Closed -$6K – 2313
2020
Q4 		$6K Buy
+1
New +$8.86K ﹤0.01% 2260

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

Nisa Investment Advisors's QNCX Position: Q2 2022 in Review

Nisa Investment Advisors sold out of Quince Therapeutics (QNCX) in Q2 2022, closing a stake of 16 shares — an estimated $20K sold.

Nisa Investment Advisors first reported a position in QNCX in Q4 2020 and held it in 4 quarters. The position peaked at $20K in Q1 2022. 66 funds tracked by Wall St. Rank hold QNCX as of Q2 2022.

  • Nisa Investment Advisors reported no remaining Quince Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Nisa Investment Advisors sold 16 Quince Therapeutics shares in Q2 2022, an estimated $20K.
  • Nisa Investment Advisors first reported a position in Quince Therapeutics in Q4 2020 and held it in 4 quarters.
  • Nisa Investment Advisors's Quince Therapeutics position peaked at $20K in Q1 2022.
  • 66 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2022.

Based on Nisa Investment Advisors's 13F filing for Q2 2022, filed 3 Aug 2022.